Bundibugyo Ebola Update: Are New Defenses on the Horizon?
Global health agencies are accelerating vaccine and therapeutic research because the Bundibugyo Ebola outbreak highlights the absence of approved countermeasures. ...
Global health agencies are accelerating vaccine and therapeutic research because the Bundibugyo Ebola outbreak highlights the absence of approved countermeasures. ...
A study finds adverse early events are linked to gut-brain disruptions in mice and humans. Medscape Medical News Source link ...
New receptor agonist combinations, a once-monthly GLP-1, and full retatrutide data are all on the agenda, along with a huge ...
The Real Ice trial in Canada pumped seawater from below the ice sheet onto the surfaceReal Ice Each winter, Canada ...
UPV researchers created the FMB scale, a continuous index that ranks medications by driving risk more precisely than DRUID and ...
Psilocybin added to psychotherapy is associated with a greater likelihood of abstinence in cocaine use disorder than an adjunct active ...
Changes in gut microbiome diversity are observed with certain antibiotic drugs years later, even after just one course of therapy. ...
BBC Panorama has seen documents and spoken to former midwives from Nottingham University Hospitals NHS Trust. Source link : https://www.bbc.com/news/articles/c152y8j4gljo?at_medium=RSS&at_campaign=rss ...
Women tell the BBC presenter how endometriosis affects their lives, as she challenges ministers to take action. Source link : ...
BP-lowering regimens with angiotensin receptor blockers are linked to a lower risk for discontinuation due to adverse events, while other ...
Parents of children with food allergies may experience a greater psychosocial burden when reactions are more frequent or severe and ...
The drug has been hailed as a breakthrough in managing the deadliest of all the major cancers. Source link : ...
Sudden cardiac death can happen without warning, and it's not just a problem for sporty young men, say experts. Source ...
In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than ...
CHICAGO -- A paradigm-changing clinical trial in prostate cancer showed that perioperative apalutamide (Erleada) and androgen deprivation therapy (ADT) significantly ...
A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced ...
"The light goes out of their eyes in about 3 years. This is not what they signed up for." -- ...
CHICAGO -- A first-in-class bispecific antibody targeting PD-1 and VEGF combined with chemotherapy significantly improved overall survival (OS) in patients ...
Donald Trump's physician says the president is in "excellent health" and is "fully fit" to serve as commander in chief ...
New data now show that perioperative systemic therapy with apalutamide can improve outcomes after radical prostatectomy. Medscape Medical News Source ...
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| 1 | 2 | |||||
| 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| 17 | 18 | 19 | 20 | 21 | 22 | 23 |
| 24 | 25 | 26 | 27 | 28 | 29 | 30 |
| 31 | ||||||
© 2022 NewsHealth.
© 2022 NewsHealth.